158102-93-3

Upstream product

• 158102-91-1 (3R,4R)-3-(5-Amino-2-methoxy-benzyl)-chroman-4,6-diol 
• 123094-61-1 6-benzyloxychroman-4-one 
• 5802-17-5 6-methoxychroman-4-one 
• 80096-64-6 6-hydroxy-2,3-dihydro-4H-chromen-4-one 
• 251639-70-0 3-{6-benzyloxy-4-[2-tert-butoxycarbonylamino-3-(1H-indol-3-yl)-propionyloxy]-chroman-3-ylmethyl}-4-methoxy-benzoic acid methyl ester 
• 251639-71-1 [3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-phenyl]-carbamic acid benzyl ester 
• 158102-89-7 3-((3R,4R)-6-Benzyloxy-4-hydroxy-chroman-3-ylmethyl)-4-methoxy-benzoic acid 
• 158102-86-4 3-(6-Benzyloxy-4-oxochroman-3-ylmethyl)-4-methoxybenzoic acid methyl ester 

Relevant academic research and scientific papers

Discovery of CP-199,330 and CP-199,331: Two potent and orally efficacious cysteinyl LT1 receptor antagonists devoid of liver toxicity

CP-199,330 (3) and CP-199,331 (4) are cysLT1 receptor antagonists that are equipotent to marketed cysLT1 receptor antagonists zafirlukast and pranlukast, show good pharmacokinetics in rats and monkeys, and are devoid of liver toxicity in monkeys as seen in CP-85,958 (1).

SULFONAMIDE DERIVATIVES OF BENZENEFUSED HYDROXY SUBSTITUTED CYCLOALKYL AND HETEROCYCLIC RING COMPOUNDS

Compounds of the formula STR1 and pharmaceutically acceptable salts and prodrugs thereof, wherein X 1, Ar, X, Y 1, R. sup.1, R. sup.2, R 3, R 5 and n are defined below, which are inhibitors of the production of leukotrienes and/or blockers of leukotriene